stockrow
Friday 6 November 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
39.96
0.39
−0.97%
Follow MDLN
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
50.68 | 50.68 | 50.68 | 50.68 |
+4 more quarters Free account |
P/S ratio |
0.99 | 1.14 | 1.27 | 0.00 | |
P/FCF ratio |
9.81 | 14.67 | 15.96 | 10.06 | |
P/Operating CF |
29.67 | 47.27 | 88.46 | 19.51 | |
P/B ratio |
1.57 | 1.77 | 1.88 | 1.76 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.31 | 1.47 | 1.63 | 0.00 | |
EV/EBITDA |
4.01 | 4.35 | 4.58 | 0.00 | |
EV/Operating CF |
10.35 | 14.24 | 15.41 | 10.16 | |
EV/FCF |
13.00 | 18.97 | 20.48 | 13.20 | |
Quick Ratio |
1.21 | 2.34 | 2.33 | 2.20 | |
Current Ratio |
4.04 | 4.33 | 4.41 | 4.29 | |
Net Debt/EBITDA |
0.00 | 14.91 | 15.05 | 1.36 | |
Debt/Assets |
31.31% | 31.96% | 32.22% | 32.64% | |
Debt/Equity |
0.65 | 0.66 | 0.65 | 0.65 | |
Asset Turnover |
0.81 | 1.51 | 0.76 | 0.00 | |
Operating CF/Net income |
5.26 | 11.92 | 3.19 | 9.58 | |
Capex/Depreciation |
0.00 | (0.41) | (0.36) | (0.42) | |
Interest Coverage |
4.24 | 3.32 | 3.10 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.03% | 16.85% | 16.70% | 0.00% | |
Intangible Assets out of Total Assets |
0.53 | 0.55 | 0.56 | 0.57 | |
Share Based Compensation of Revenue |
0.37% | 0.38% | 0.31% | 0.00% | |
Graham Net Nets |
(0.27) | (0.25) | (0.23) | (0.25) | |
Graham Number |
18.46 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.97% | 1.97% | 1.97% | 1.97% | |
Free Cash Flow Yield |
10.20% | 6.82% | 6.27% | 9.94% | |
Revenue per Share |
8.96 | 8.97 | 8.98 | 9.61 | |
Operating CF per Share |
1.17 | 0.83 | 0.50 | 2.15 | |
Capex per Share |
(0.16) | (0.13) | (0.12) | (0.55) | |
Free Cash Flow per Share |
1.01 | 0.70 | 0.39 | 1.60 | |
Cash per Share |
0.00 | 3.12 | 2.73 | 2.39 | |
Shareholders Equity per Share |
22.12 | 22.26 | 23.63 | 23.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.12 | 22.26 | 23.63 | 23.81 | |
Free Cash Flow |
884.00 | 604.00 | 316.00 | 1,297.00 | |
Working Capital |
9,524.00 | 9,032.00 | 8,644.00 | 8,189.00 | |
Capital Expenditures |
(141.00) | (111.00) | (96.00) | (447.00) | |
Net Current Asset Value |
(8,139.00) | (8,531.00) | (8,485.00) | (8,519.00) | |
EV/EBIT |
4.43 | 4.73 | 4.97 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.06 | |
Price to Operating Income |
3.34 | 3.66 | 3.87 | 0.00 | |
| Other line items | |||||
Average Receivables |
3,506.50 | — | — | — | |
Average Payables |
1,039.00 | — | — | — | |
Average Inventory |
4,631.00 | — | — | — | |
Average Assets |
38,078.00 | 19,675.00 | 37,496.00 | 19,242.00 | |
Average Common Equity |
17,772.00 | — | — | — |
Columns are period end dates · fundamentals updated 4 Nov 2026